---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-178949"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:46:38.316839+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nkarta reports Q2 net loss of $23M, cash of $334M; NKX019 data expected H2 2025

## Summary
- Net loss of $23.0M ($0.31 per share) for Q2 2025.
- Cash, equivalents and investments of $334.0M as of June 30, 2025; runway into 2029.
- R&D expenses of $20.8M; G&A expenses of $6.4M for Q2 2025.
- Preliminary NKX019 autoimmune data (Ntrust-1 and Ntrust-2) expected H2 2025.
- Shawn Rose, M.D., Ph.D appointed Chief Medical Officer and Head of R&D in June 2025.

## SEC filing metadata
- accession: 0001193125-25-178949
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000119312525178949/0001193125-25-178949-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000119312525178949/nktx-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-178949
- JSON: https://secwatch.observer/filing/0001193125-25-178949.json
- Plain text: https://secwatch.observer/filing/0001193125-25-178949.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.